{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:04:35Z","timestamp":1789837475679,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this study, we aimed to test if the schizophrenia (SCZ) polygenic risk score (PRS) was associated with clinical symptoms in (a) the first episode of psychosis pre-treatment (FEP), (b) at nine weeks after initiation of risperidone treatment (FEP-9W) and (c) with the response to risperidone. We performed a detailed clinical assessment of 60 FEP patients who were antipsychotic-naive and, again, after nine weeks of standardized treatment with risperidone. After blood collection and DNA isolation, the samples were genotyped using the Illumina PsychArrayChip and then imputed. To calculate PRS, we used the latest available GWAS summary statistics from the Psychiatric Genomics Consortium wave-2 SCZ group as a training set. We used Poisson regression to test association between PRS and clinical measurements correcting for the four principal components (genotyping). We considered a p-value &lt;\u20090.0014 (Bonferroni correction) as significant. First, we verified that the schizophrenia PRS was also able to distinguish cases from controls in this south-eastern Brazilian sample, with a similar variance explained to that seen in Northern European populations. In addition, within-cases analyses, we found that PRS is significantly correlated with baseline (pre-treatment) symptoms, as measured by lower clinical global assessment of functioning (\u2212GAF), higher depressive symptoms and higher scores on a derived excitement factor. After standardized treatment for nine weeks, the correlation with GAF and the excitement factor disappeared while depressive symptoms became negatively associated with PRS. We conclude that drug (and other treatments) may confound attempts to understand the aetiological influence on symptomatology of polygenic risk scores. These results highlight the importance of studying schizophrenia, and other disorders, pre-treatment to understand the relationship between polygenic risk and phenotypic features.<\/jats:p>","DOI":"10.1038\/s41398-018-0230-7","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T18:07:11Z","timestamp":1535738831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort"],"prefix":"10.1038","volume":"8","author":[{"given":"Marcos Leite","family":"Santoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia M.","family":"Spindola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Talarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Gouvea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyuck","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamel","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1843-9842","authenticated-orcid":false,"given":"Stephen","family":"Newhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Muniz","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ary","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quirino","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Affonseca","family":"Bressan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sintia Iole","family":"Belangero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerome","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"230_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1192\/S0007125000297663","volume":"172","author":"M Birchwood","year":"1998","unstructured":"Birchwood, M., Todd, P. & Jackson, C. Early intervention in psychosis. The critical period hypothesis. Br. J. Psychiatry Suppl. 172, 53\u201359 (1998).","journal-title":"Br. J. Psychiatry Suppl."},{"key":"230_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/schbul\/sbr100","volume":"38","author":"A Demjaha","year":"2012","unstructured":"Demjaha, A., MacCabe, J. H. & Murray, R. M. How genes and environmental factors determine the different neurodevelopmental trajectories of schizophrenia and bipolar disorder. Schizophr. Bull. 38, 209\u2013214 (2012).","journal-title":"Schizophr. Bull."},{"key":"230_CR3","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.jpsychires.2013.07.019","volume":"47","author":"M Fuste","year":"2013","unstructured":"Fuste, M. et al. Reduced expression of SP1 and SP4 transcription factors in peripheral blood mononuclear cells in first-episode psychosis. J. Psychiatr. Res 47, 1608\u20131614 (2013).","journal-title":"J. Psychiatr. Res"},{"key":"230_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/archpsyc.60.12.1187","volume":"60","author":"PF Sullivan","year":"2003","unstructured":"Sullivan, P. F., Kendler, K. S. & Neale, M. C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 60, 1187\u20131192 (2003).","journal-title":"Arch. Gen. Psychiatry"},{"key":"230_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics Consortium.","year":"2014","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421\u2013427 (2014).","journal-title":"Nature"},{"key":"230_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1073\/pnas.58.1.199","volume":"58","author":"II Gottesman","year":"1967","unstructured":"Gottesman, I. I. & Shields, J. A polygenic theory of schizophrenia. Proc. Natl. Acad. Sci. USA 58, 199\u2013205 (1967).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"230_CR7","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1101\/gr.6665407","volume":"17","author":"NR Wray","year":"2007","unstructured":"Wray, N. R., Goddard, M. E. & Visscher, P. M. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res 17, 1520\u20131528 (2007).","journal-title":"Genome Res"},{"key":"230_CR8","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nature08185","volume":"460","author":"SM Purcell","year":"2009","unstructured":"Purcell, S. M. et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748\u2013752 (2009).","journal-title":"Nature"},{"key":"230_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003348","volume":"9","author":"F Dudbridge","year":"2013","unstructured":"Dudbridge, F. Power and predictive accuracy of polygenic risk scores. PLoS Genet 9, e1003348 (2013).","journal-title":"PLoS Genet"},{"key":"230_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037852","volume":"7","author":"EM Derks","year":"2012","unstructured":"Derks, E. M., Vorstman, J. A., Ripke, S., Kahn, R. S. & Ophoff, R. A. Investigation of the genetic association between quantitative measures of psychosis and schizophrenia: a polygenic risk score analysis. PLoS One 7, e37852 (2012).","journal-title":"PLoS One"},{"key":"230_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/schbul\/sbr190","volume":"39","author":"E Walton","year":"2013","unstructured":"Walton, E. et al. Cumulative genetic risk and prefrontal activity in patients with schizophrenia. Schizophr. Bull. 39, 703\u2013711 (2013).","journal-title":"Schizophr. Bull."},{"key":"230_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.60","volume":"2","author":"HC Whalley","year":"2012","unstructured":"Whalley, H. C. et al. The influence of polygenic risk for bipolar disorder on neural activation assessed using fMRI. Transl. Psychiatry 2, e130 (2012).","journal-title":"Transl. Psychiatry"},{"key":"230_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.biopsych.2013.01.027","volume":"74","author":"HC Whalley","year":"2013","unstructured":"Whalley, H. C. et al. Polygenic risk and white matter integrity in individuals at high risk of mood disorder. Biol. Psychiatry 74, 280\u2013286 (2013).","journal-title":"Biol. Psychiatry"},{"key":"230_CR14","doi-asserted-by":"publisher","first-page":"18087","DOI":"10.1523\/JNEUROSCI.2531-12.2012","volume":"32","author":"AJ Holmes","year":"2012","unstructured":"Holmes, A. J. et al. Individual differences in amygdala-medial prefrontal anatomy link negative affect, impaired social functioning, and polygenic depression risk. J. Neurosci. 32, 18087\u201318100 (2012).","journal-title":"J. Neurosci."},{"key":"230_CR15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.biopsych.2016.06.028","volume":"81","author":"E Vassos","year":"2017","unstructured":"Vassos, E. et al. An examination of polygenic score risk prediction in individuals with first-episode psychosis. Biol. Psychiatry 81, 470\u2013477 (2017).","journal-title":"Biol. Psychiatry"},{"key":"230_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1001\/jamapsychiatry.2015.3058","volume":"73","author":"HJ Jones","year":"2016","unstructured":"Jones, H. J. et al. Phenotypic manifestation of genetic risk for schizophrenia during adolescence in the general population. JAMA Psychiatry 73, 221\u2013228 (2016).","journal-title":"JAMA Psychiatry"},{"key":"230_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.schres.2016.11.039","volume":"184","author":"SM Sengupta","year":"2017","unstructured":"Sengupta, S. M. et al. Polygenic risk score associated with specific symptom dimensions in first-episode psychosis. Schizophr. Res 184, 116\u2013121 (2017).","journal-title":"Schizophr. Res"},{"key":"230_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1590\/S1516-44462007000300010","volume":"29","author":"MS Lima","year":"2007","unstructured":"Lima, M. S. et al. The Portuguese version of the clinical global impression-schizophrenia scale: validation study. Rev. Bras. Psiquiatr 29, 246\u2013249 (2007).","journal-title":"Rev. Bras. Psiquiatr"},{"key":"230_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0920-9964(98)00029-2","volume":"32","author":"RA Bressan","year":"1998","unstructured":"Bressan, R. A., Chaves, A. C., Shirakawa, I. & de Mari, J. Validity study of the Brazilian version of the calgary depression scale for schizophrenia. Schizophr. Res 32, 41\u201349 (1998).","journal-title":"Schizophr. Res"},{"key":"230_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","volume":"137","author":"RS Wallwork","year":"2012","unstructured":"Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R. & Dickinson, D. Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia. Schizophr. Res 137, 246\u2013250 (2012).","journal-title":"Schizophr. Res"},{"key":"230_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1590\/1516-4446-2013-1330","volume":"36","author":"CH Higuchi","year":"2014","unstructured":"Higuchi, C. H. et al. Factor structure of the positive and negative syndrome scale (PANSS) in Brazil: convergent validation of the Brazilian version. Rev. Bras. Psiquiatr 36, 336\u2013339 (2014).","journal-title":"Rev. Bras. Psiquiatr"},{"key":"230_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","volume":"438","author":"S Leucht","year":"2009","unstructured":"Leucht, S., Davis, J. M., Engel, R. R., Kissling, W. & Kane, J. M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr. Scand. Suppl. 438, 7\u201314 (2009).","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"230_CR23","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4088\/JCP.v69n0805","volume":"69","author":"H Reeves","year":"2008","unstructured":"Reeves, H. et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J. Clin. Psychiatry 69, 1228\u20131336 (2008).","journal-title":"J. Clin. Psychiatry"},{"key":"230_CR24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.7326\/0003-4819-147-9-200711060-00003","volume":"147","author":"RA Mahmoud","year":"2007","unstructured":"Mahmoud, R. A. et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann. Intern Med 147, 593\u2013602 (2007).","journal-title":"Ann. Intern Med"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0230-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0230-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0230-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:28:19Z","timestamp":1671535699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0230-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["230"],"URL":"https:\/\/doi.org\/10.1038\/s41398-018-0230-7","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"19 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.A.B. reports grants and non-financial support from Funda\u00e7\u00e3o de Amparo a Pesquisa de S\u00e3o Paulo (FAPESP\/2016\/02246-5), Brasil; grants and non-financial support from Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnologia (CNPq), Brasil, personal fees and non-financial support from Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior (CAPES), Brasil, during the conduct of the study; grants, personal fees and non-financial support from Janssen, personal fees from Ache Laborat\u00f3rios Farmac\u00eauticos, grants and personal fees from Roche, outside the submitted work. S.D.J. funding: S.D.J. was part supported by NARSAD Young Investigator Grant (YI 60373) and European Union\u2019s Horizon 2020 research and innovation programme (Marie Sklodowska-Curie grant agreement 658195). The other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"174"}}